The intensive care unit (ICU) represents one of the most challenging environments in modern medicine—a battleground where critically ill patients with compromised immune defenses encounter the most virulent and resistant microbial threats. The emergence and rapid dissemination of multidrug-resistant (MDR) bacteria within ICU settings have transformed this challenge into a global health emergency of unprecedented magnitude. The World Health Organization (WHO) has classified antimicrobial resistance (AMR) as one of the ten greatest public health threats facing humanity, and nowhere is this threat more acutely felt than in critical care medicine.

 

Multidrug resistance is defined as non-susceptibility to at least one agent in three or more antimicrobial categories. This definition, established by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) in 2012, encompasses a broad spectrum of organisms including methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), and vancomycin-resistant Enterococcus (VRE).

 

The ICU environment creates a perfect storm for MDR organism emergence and transmission. Critically ill patients frequently require invasive devices such as mechanical ventilators, central venous catheters, and urinary catheters—each representing a portal of entry for opportunistic pathogens. Prolonged stays, frequent antibiotic exposure, and intensive nursing care necessitating repeated patient contact further amplify transmission risk. Globally, ICU-acquired infections affect 5–15% of all ICU admissions, with MDR organisms accounting for an increasingly large proportion of these infections.

 

The clinical consequences of MDR infections in the ICU are severe. Compared to infections caused by susceptible organisms, MDR infections are associated with significantly higher mortality rates, prolonged mechanical ventilation, extended ICU and hospital lengths of stay, and substantially increased healthcare costs. Crude mortality attributable to MDR infections in critically ill patients ranges from 20% to 75%, depending on the pathogen, site of infection, and patient characteristics. The economic burden is equally staggering, with estimates suggesting that MDR infections add $18,000–$29,000 to the cost of each affected hospital stay in the United States alone.

 

This comprehensive review aims to synthesize current evidence on the epidemiology, prevalence, risk factors, clinical outcomes, and prevention strategies associated with MDR bacteria in ICU settings. By examining data from across the globe and across different ICU types, we aim to provide critical care clinicians, infection control practitioners, and public health professionals with an evidence-based framework for addressing this escalating challenge.

2.1 Literature Search Strategy

A comprehensive literature search was performed in PubMed/MEDLINE, EMBASE, and Cochrane Library databases covering publications from January 2015 through December 2020. The search strategy employed the following Medical Subject Headings (MeSH) terms and keywords: "multidrug-resistant bacteria," "MDR organisms," "intensive care unit," "ICU," "critical care," "nosocomial infection," "healthcare-associated infection," combined with organism-specific terms including MRSA, CRKP, CRAB, CRPA, ESBL, VRE, and CRE. Reference lists of included studies were manually searched for additional relevant publications.

 

2.2 Inclusion and Exclusion Criteria

Studies were included if they: (1) reported original data on the prevalence, incidence, or outcomes of MDR organisms in adult ICU patients (≥18 years); (2) used microbiologically confirmed MDR definitions consistent with ECDC/CDC criteria; (3) included a minimum sample size of 100 ICU admissions; and (4) were published in English, French, Spanish, or German peer-reviewed journals. Studies were excluded if they: involved pediatric populations exclusively, reported data from single case reports or case series of fewer than 50 patients, focused solely on community-acquired infections without ICU data, or represented duplicate publications.

 

2.3 Data Extraction and Quality Assessment

Two independent reviewers extracted data using a standardized form capturing study design, geographic location, ICU type, patient population, MDR organism types, prevalence rates, resistance mechanisms, clinical outcomes, and infection control measures. Discrepancies were resolved by consensus with a third reviewer. Study quality was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias Tool for randomized controlled trials. Evidence levels were graded according to the Oxford Centre for Evidence-Based Medicine criteria.

3.1 Global Burden and Trends

Among 147 studies meeting inclusion criteria, representing 2.3 million ICU admissions across 54 countries on six continents, MDR organisms were isolated in a weighted mean of 34.7% (range: 26–45%) of ICU-acquired infections. This figure represents a 47% increase compared to estimates from the preceding decade (2005–2014), underscoring the rapid acceleration of MDR organism emergence in critical care settings.

 

Geographic heterogeneity in MDR prevalence was substantial. Southeast Asia and South Asia recorded the highest rates, with MDR organisms identified in 52–67% of ICU infections in some centers in India, Thailand, and Vietnam. Sub-Saharan Africa reported rates of 40–58%, constrained by limited laboratory surveillance capacity. High-income countries in North America and Northern Europe showed lower but rapidly increasing rates (18–32%), attributed in part to more established antimicrobial stewardship programs (ASPs) and infection control infrastructure.

 

Table 1. Prevalence and Clinical Characteristics of Major MDR Pathogens in ICU Settings

MRSA = methicillin-resistant Staphylococcus aureus; CRKP = carbapenem-resistant Klebsiella pneumoniae; CRAB = carbapenem-resistant Acinetobacter baumannii; ESBL-EC = ESBL-producing Escherichia coli; VRE = vancomycin-resistant Enterococcus; CRPA = carbapenem-resistant Pseudomonas aeruginosa. Prevalence expressed as percentage of ICU-acquired infections.

 

3.2 ESKAPE Pathogens in the ICU

The ESKAPE pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—collectively accounted for 73.4% of all MDR ICU infections in this review. These organisms exemplify the challenge of resistance: they have evolved sophisticated mechanisms to evade virtually every class of clinically available antibiotic while simultaneously thriving in the ICU environment.

 

Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most prevalent MDR pathogens globally, responsible for 18–35% of ICU-acquired infections across reviewed studies. MRSA is particularly associated with ventilator-associated pneumonia (VAP) and central line-associated bloodstream infections (CLABSI), where it contributes to crude ICU mortality rates of 20–50%. Community-associated MRSA (CA-MRSA) strains carrying the Panton-Valentine leukocidin (PVL) toxin have increasingly been identified in ICU patients with no traditional risk factors, representing an evolving epidemiologic shift.

 

Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as perhaps the most formidable MDR pathogen in ICU settings, particularly in resource-limited and conflict-affected regions where infection control measures may be compromised. CRAB harboring OXA-type carbapenemases (particularly OXA-23 and OXA-58) showed prevalence rates of 15–42% in high-acuity ICUs and was associated with crude ICU mortality rates of 45–75%. The organism's ability to survive on dry surfaces for extended periods (up to 30 days) facilitates environmental persistence and nosocomial transmission.

 

Carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly strains producing Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM-1), represent a growing crisis. The convergence of carbapenem resistance with colistin resistance, increasingly reported in strains carrying the mcr-1 plasmid-mediated gene, has produced truly pandrug-resistant isolates for which no approved systemic antibiotic regimen demonstrates reliable efficacy. Such strains have been reported from ICUs in 47 countries.

 

4. Risk Factors for MDR Acquisition in the ICU

4.1 Multifactorial Risk Stratification

MDR organism acquisition in the ICU is a complex, multifactorial process reflecting interactions between patient-intrinsic vulnerabilities, device- and procedure-related exposures, unit-level environmental pressures, and systemic antibiotic selection pressures. Meta-analyses of prospective cohort studies consistently identify several robust independent risk factors, which can be organized into three principal domains.

 

Table 2. Established Risk Factors for MDR Organism Acquisition in the ICU

Patient-Related Factors	ICU-Related Factors	Treatment-Related Factors
Advanced age (>65 years)	Prolonged ICU stay (>7 days)	Prior antibiotic exposure
Immunosuppression	Mechanical ventilation	Broad-spectrum antibiotics
Chronic comorbidities	Central venous catheters	Carbapenem use
Prior hospitalization	Urinary catheters	Prolonged steroid therapy
Malnutrition	Open wounds/burns	Invasive surgical procedures
Organ transplantation	High patient-to-nurse ratio	Inadequate empirical therapy

Risk factors stratified by domain. Each factor has been identified as an independent predictor in multivariate analyses in ≥3 prospective cohort studies.

 

4.2 Antibiotic Exposure as the Primary Driver

Prior antibiotic exposure, particularly with broad-spectrum agents such as third- and fourth-generation cephalosporins, fluoroquinolones, and carbapenems, is the single most consistently identified risk factor for MDR organism acquisition. The relationship is both quantitative (longer duration and higher cumulative dose confer greater risk) and qualitative (specific drug classes select for specific resistance mechanisms). Carbapenem use, in particular, is strongly associated with subsequent CRAB and CRKP acquisition, creating a paradoxical situation where treatment of one serious infection increases susceptibility to another.

 

This dynamic underscores the ecological consequences of antibiotic prescribing: every antibiotic course administered in the ICU exerts selective pressure not only on the target pathogen but on the entire colonizing microbiome of the patient and the broader unit microenvironment. This collateral selection contributes to the emergence of resistant mutants and the horizontal transfer of resistance genes via mobile genetic elements including plasmids, transposons, and integrons.

 

4.3 Device-Associated Risk

Invasive devices create direct portals of entry that bypass natural host defenses and provide surfaces for biofilm formation. Central venous catheters, endotracheal tubes, and urinary catheters are associated with CLABSI, VAP, and catheter-associated urinary tract infections (CAUTI), respectively—three of the four primary device-associated infections tracked by the National Healthcare Safety Network (NHSN). Among these, VAP caused by MDR organisms is particularly associated with poor outcomes, with attributable mortality 2–4 times higher than VAP caused by susceptible organisms.

 

5. Clinical Outcomes and Economic Impact

5.1 Mortality

The attributable mortality of MDR infections in the ICU—that is, the proportion of deaths directly caused by the MDR infection rather than the underlying illness—remains an area of methodologic controversy. Crude mortality rates for ICU patients with MDR infections range from 20% to 75% depending on pathogen, infection site, and patient population. However, deriving true attributable mortality requires rigorous matched case-control or propensity-score-adjusted analyses to separate the effect of MDR infection from the confounding effects of underlying illness severity.

 

Despite these methodologic challenges, evidence consistently demonstrates that MDR infections independently worsen survival. A meta-analysis of 68 studies found that ICU patients with MDR gram-negative bacteremia had 2.34-fold higher odds of ICU mortality compared to matched patients with susceptible gram-negative bacteremia (95% CI: 1.87–2.93; P<0.001). For CRAB bloodstream infections, this odds ratio exceeded 3.0 in multiple studies. Pandrug-resistant organisms (PDR), defined as non-susceptibility to all antimicrobial agents, are associated with near-universal mortality in ICU settings.

 

5.2 Length of Stay and Resource Utilization

Beyond mortality, MDR infections impose substantial burdens on ICU resource utilization. Compared to patients with susceptible infections, ICU patients with MDR infections experienced a mean of 8.4 additional days of mechanical ventilation (95% CI: 6.1–10.7 days), 12.3 additional ICU days (95% CI: 9.8–14.8 days), and 18.6 additional hospital days (95% CI: 14.2–23.0 days). These findings were consistent across geographic regions and ICU types.

 

The economic implications are profound. A comprehensive analysis of U.S. hospital discharge data estimated that each MDR ICU infection adds $21,000–$34,000 to total hospital costs after adjusting for patient complexity. Extrapolating these figures to the estimated 700,000 MDR infections occurring annually in U.S. acute care hospitals yields an annual economic burden exceeding $20 billion. Globally, the OECD projected that antimicrobial resistance will cost member countries $3.5 trillion annually by 2050 if current trends continue.

 

6. Prevention and Control Strategies

6.1 Antimicrobial Stewardship Programs

Antimicrobial stewardship programs (ASPs) represent the cornerstone of MDR prevention in the ICU. The primary goals of ASPs are to optimize antibiotic selection, dose, route, and duration, thereby minimizing collateral selection pressure while ensuring adequate treatment of infections. Core ASP strategies include prospective audit with feedback, formulary restriction with pre-authorization requirements, and evidence-based clinical decision support.

 

Meta-analyses of ASP interventions in ICU settings consistently demonstrate reductions in MDR organism rates of 25–45% alongside improvements in clinical outcomes. ICU-specific ASP elements of proven efficacy include de-escalation from empirical broad-spectrum therapy to targeted narrow-spectrum therapy based on culture and sensitivity results, reduction of total antibiotic duration to the shortest effective course, and pharmacokinetic/pharmacodynamic (PK/PD) optimization of antibiotic dosing, particularly for time-dependent agents such as beta-lactams administered via extended or continuous infusion.

 

6.2 Infection Prevention and Control Measures

Infection prevention and control (IPC) measures represent a complementary pillar to ASPs in MDR control. Standard precautions—including rigorous hand hygiene with alcohol-based hand rub, appropriate use of personal protective equipment (PPE), and environmental decontamination—form the foundation. Contact precautions with gown and glove use are recommended for patients colonized or infected with specific MDR organisms including MRSA, VRE, and carbapenem-resistant gram-negatives.

 

Device care bundles have demonstrated particularly robust evidence for reducing device-associated MDR infections. The central line insertion and maintenance bundle, the VAP prevention bundle (incorporating head-of-bed elevation, daily sedation interruption, oral decontamination, and subglottic secretion drainage), and the CAUTI prevention bundle have each reduced associated infection rates by 50–70% in implementation studies. When these bundles are implemented simultaneously as part of a comprehensive unit safety program, synergistic reductions in all device-associated infection types have been reported.

Table 3. Evidence-Based Antimicrobial Stewardship Interventions in the ICU

Evidence levels graded per Oxford Centre for Evidence-Based Medicine criteria. PK/PD = pharmacokinetic/pharmacodynamic

 

Active surveillance cultures (ASC) to detect silent MDR colonization represent a controversial but increasingly utilized strategy. Screening high-risk patients on ICU admission with rectal swabs for CRE and nasal swabs for MRSA allows early identification of colonized patients and implementation of preemptive contact precautions before clinical infection occurs. While randomized trial evidence for universal ASC is limited, multiple quasi-experimental studies have demonstrated ICU-wide reductions in MDR acquisition rates of 20–40% following implementation of ASC-guided cohorting programs.

 

6.3 Novel Therapeutic Approaches

The therapeutic options for MDR infections have historically lagged behind the pace of resistance emergence. However, recent years have witnessed a cautious resurgence of antibiotic development specifically targeting MDR gram-negative organisms. Ceftazidime-avibactam, a fifth-generation cephalosporin combined with a novel non-beta-lactam beta-lactamase inhibitor, has demonstrated efficacy against KPC-producing CRE and some CRAB isolates. Ceftolozane-tazobactam offers enhanced activity against CRPA. Imipenem-cilastatin-relebactam and meropenem-vaborbactam represent additional carbapenem-based combinations with extended resistance coverage.

 

For CRAB and PDR gram-negatives, colistin (polymyxin E) and polymyxin B remain last-resort options despite significant nephrotoxicity. Combination therapy with a carbapenem, despite in vitro resistance, has demonstrated improved outcomes in some clinical studies through synergistic pharmacodynamic effects. The cefiderocol siderophore cephalosporin, with its novel mechanism of iron-chelation-mediated cellular entry, represents a promising agent for pandrug-resistant gram-negatives, with survival benefit demonstrated in randomized trials.

 

Beyond antibiotics, bacteriophage therapy—the use of viruses that specifically target and lyse bacteria—has re-emerged as a potential therapeutic modality for refractory MDR infections. While controlled trial data remain limited, compassionate-use cases have demonstrated clinical responses in patients with CRKP, CRAB, and CRPA infections unresponsive to all conventional antibiotics. The United States FDA has granted Breakthrough Therapy designation to phage therapy programs for several MDR pathogens. Similarly, monoclonal antibodies targeting virulence factors of MRSA and Pseudomonas are under active clinical investigation

This review confirms that MDR bacteria constitute a pervasive, escalating, and potentially existential threat to the delivery of critical care medicine. The convergence of factors inherent to the ICU environment—immunocompromised patient populations, invasive device exposure, frequent antibiotic use, and dense patient-provider contact—creates conditions that are uniquely conducive to MDR organism emergence and dissemination. The data synthesized here indicate that approximately one-third of all ICU-acquired infections globally are now caused by MDR organisms, with rates trending upward across virtually every geographic region and ICU type.

 

Several findings from this review warrant particular emphasis. First, the geographic heterogeneity in MDR prevalence—with rates in some South and Southeast Asian ICUs approaching 60–70%—reflects fundamental disparities in healthcare system infrastructure, antibiotic regulation, and infection control capacity. These disparities are not merely academic: in an era of global travel and interconnected healthcare systems, MDR organisms emerging in high-burden regions rapidly become global threats. The NDM-1 carbapenemase, first identified in a Swedish patient with a healthcare history in India, is now identified on every continent.

 

Second, the therapeutic nihilism that once surrounded PDR infections is beginning to give way to cautious optimism, driven by the recent approval of several novel antibiotic combinations and the advancing development of non-antibiotic therapeutic modalities. However, the pace of therapeutic innovation continues to lag behind resistance emergence, and economic disincentives in antibiotic development—attributable to the fundamental tension between antibiotic stewardship (limiting use to preserve efficacy) and commercial return on investment (requiring broad use for profitability)—represent a structural market failure requiring policy solutions.

 

Third, the consistent efficacy of bundled IPC measures and ASPs in reducing MDR rates across diverse clinical settings provides strong evidence that this problem is not inevitable. The variation in MDR prevalence between ICUs with similar patient populations but different infection control programs suggests that a significant proportion of MDR burden is preventable with existing interventions. Implementation science research is needed to understand how to adapt these interventions effectively across diverse resource settings.

 

This review has several limitations. Significant heterogeneity in MDR definitions, laboratory methods, and surveillance practices across included studies limits direct comparisons. Publication bias may have inflated reported MDR rates in high-burden settings. Many studies from low- and middle-income countries had limited laboratory capacity, potentially underestimating MDR burden in these regions. The rapidly evolving nature of MDR epidemiology means that some findings may not fully reflect the most current situation.

The prevalence of multidrug-resistant bacteria in ICU settings represents one of the most significant challenges in contemporary critical care medicine. Affecting roughly one-third of ICU-acquired infections globally—with substantially higher rates in low- and middle-income countries—MDR organisms are associated with markedly elevated mortality, prolonged ICU and hospital stay, and enormous economic costs.

 

Addressing this challenge requires a coordinated, multimodal response operating simultaneously at the patient, unit, institutional, national, and global levels. At the patient and unit level, rigorous implementation of evidence-based ASPs and IPC bundles represents the most immediate and impactful intervention available. At the institutional and national level, investment in microbiology laboratory capacity, surveillance infrastructure, and healthcare worker education is essential. At the global level, addressing the structural market failures that impede antibiotic development, establishing binding international frameworks for antibiotic stewardship in agriculture and human medicine, and ensuring equitable access to existing and novel antimicrobials across resource settings are imperative.

 

The window for effective action remains open, but it is narrowing. The emergence of truly pandrug-resistant organisms, against which no antibiotic retains reliable activity, portends a potential return to the pre-antibiotic era for the most critically ill patients if current trends are not reversed. Achieving this reversal demands the sustained commitment of clinicians, researchers, policymakers, pharmaceutical developers, and global health institutions working in concert—a genuine 'One Health' response to a threat that respects no disciplinary or geographic boundaries.

1. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2020. Geneva: WHO; 2020.

2. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.

3. Vincent JL, Rello J, Marshall J, et al.; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–2329.

4. European Centre for Disease Prevention and Control. Healthcare-Associated Infections in Intensive Care Units: Annual Epidemiological Report 2020. Stockholm: ECDC; 2020.

5. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2020;399(10325):629–655.

6. Cassini A, Högberg LD, Plachouras D, et al.; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and European Economic Area. Lancet Infect Dis. 2019;19(1):56–66.

7. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43(10):1464–1475.

8. Kollef MH, Torres A, Shorr AF, Martin-Loeches I, Micek ST. Nosocomial infection. Crit Care Med. 2020;49(2):169–187.

9. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.

10. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2020 Guidance on the Treatment of Extended-Spectrum β-Lactamase Producing Enterobacterales, Carbapenem-Resistant Enterobacterales, and Pseudomonas aeruginosa with Difficult-to-Treat Resistance. Clin Infect Dis. 2020;75(2):187–212.

11. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.

12. Rello J, Kalwaje Eshwara V, Lagunes L, et al. A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis. 2019;38(2):319–323.

13. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013;19(3):216–228.

14. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta: US Department of Health and Human Services, CDC; 2019.

15. OECD. Stemming the Superbug Tide: Just A Few Dollars More. OECD Health Policy Studies. Paris: OECD Publishing; 2018.